Vebreltinib ER is under clinical development by Apollomics and currently in Phase II for Pancreatic Cancer. According to GlobalData, Phase II drugs for Pancreatic Cancer have a 25% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Vebreltinib ER’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Vebreltinib ER overview
Vebreltinib ER (Vambiru) is a potent, small molecule, orally bioavailable, and highly selective anticancer agent. It is formulated as an enteric-coated capsule for the oral route of administration. Vambiru is indicated to treat first-line, locally advanced or metastatic non-leukemia patients with mesenchymal-to-epithelial transition factor (MET) exon 14 skipping, non-small cell lung cancer (NSCLC). It is also indicated for the treatment of adult patients with isocitrate dehydrogenase (IDH) mutant astrocytoma (WHO Grade 4) or glioblastoma with a history of low-grade disease who have the PTPRZ1-MET fusion (ZM fusion) gene and have failed previous treatments.
APL-101 (CBT-101) is under development for the treatment of c-Met dysregulation advanced solid tumors such as high-grade gliomas, non-small cell lung cancer, gastric cancer, gastroesophageal junction adenocarcinoma, renal cell carcinoma, primary CNS tumor, gastric cancer, hepatic cancer, recurrent glioblastoma multiforme, pancreatic cancer, colon cancer, leptomeningeal disease (neoplastic meningitis, leptomeningeal carcinomatosis), esophageal cancer, glioblastoma multiforme. The therapeutic candidate is administered orally as a enteric coated capsule. It acts by targeting the c-Met (hepatocyte growth factor receptor). It was also under development for the treatment of advanced or metastatic hepatocellular carcinoma, and renal cell carcinoma.
Apollomics overview
Apollomics is a biotechnology company that discovers and develops oncology therapies. It is investigating APL-101, a novel small molecule c-Met inhibitor (c-METi) that targets the c-Met-dysregulated pathway in gastric, hepatic, pancreatic and lung tumors; and APL-102, an oral multi-kinase inhibitor (mKi) targeting receptor tyrosine kinase (RTKs) and serine or threonine-kinases in liver, breast, colorectal, gastric cancers. The company is also evaluating APL-106 against acute myeloid leukemia (AML); APL-108 to treat multiple myeloma (MM); APL-501 and APL-102 targeting solid tumors; APL-502 and APL-801 against multiple tumors; and APL-810 for gastroenterological cancers. It operates in Taiwan and the US. Apollomics is headquartered in Foster City, California, the US.
For a complete picture of Vebreltinib ER’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
